XALKORI Market Summary

Key Factors Driving XALKORI Growth

1. Broadening across multiple biomarker-defined cancers: XALKORI has a diversified label covering ALK- or ROS1-positive metastatic NSCLC, ALK-positive relapsed/refractory systemic anaplastic large-cell lymphoma (ALCL) in pediatric patients and young adults, and ALK-positive unresectable/recurrent/refractory inflammatory myofibroblastic tumor (IMT) in adults and children ≥1 year. This gives crizotinib multiple revenue pools beyond its original ALK-positive NSCLC market.

2. Strong clinical efficacy in ALK-positive NSCLC: The pivotal PROFILE 1005 trial enrolled 1,069 patients, with investigator-assessed objective response rates of 54% in centrally/local-tested ALK-positive patients and 41% in the locally tested subgroup. The established efficacy and long-term clinical experience continue to support use in ALK-driven disease.

3. ROS1-positive NSCLC provides an additional precision-oncology opportunity: FDA approval for ROS1-positive metastatic NSCLC was based on a 50-patient study in which XALKORI achieved a 66% objective response rate and a median response duration of 18.3 months. ROS1 rearrangements occur in approximately 1% of NSCLC, representing a defined patient population with a strong biological rationale for targeted therapy.

4. Expansion into rare ALK-positive tumors strengthens the long-term niche opportunity: FDA approved XALKORI for ALK-positive IMT in 2022, covering adults and pediatric patients ≥1 year, and for ALK-positive systemic ALCL in pediatric patients ≥1 year and young adults in 2021. Importantly, FDA orphan-drug records show U.S. exclusivity for these indications extending to 2029 for IMT and 2028 for ALCL, providing additional protection in these rare-disease segments.

5. Oral administration and established treatment experience support continued utilization: XALKORI is administered orally, with the standard metastatic NSCLC dose being 250 mg twice daily. Its more than a decade of clinical and commercial experience—U.S. approval dates back to 2011—provides physicians with substantial familiarity with its dosing, safety profile and biomarker-selected use. Pfizer also offers oral pellets, supporting administration in younger patients.

XALKORI Recent Developments

In August 2026, R Pharm received authorization to run a bioequivalence trial of a crizotinib capsule (DT CRZ, 250 mg) versus XALKORI, with up to 90 volunteers; trial authorization valid through end 2028.

“XALKORI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of XALKORI for approved indication like Anaplastic large cell lymphoma and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Non-Hodgkin’s lymphoma, Renal cell carcinoma, Neuroblastoma, and Solid tumours in the 7MM. A detailed picture of XALKORI’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the XALKORI for approved and potential indications. The XALKORI market report provides insights about XALKORI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current XALKORI performance, future market assessments inclusive of the XALKORI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of XALKORI sales forecasts, along with factors driving its market.

XALKORI Drug Summary

XALKORI is an orally administered, small-molecule tyrosine kinase inhibitor developed by Pfizer that is designed to target specific oncogenic signaling pathways, primarily the anaplastic lymphoma kinase (ALK) and ROS1 receptor tyrosine kinases, as well as MET. By inhibiting these kinases, crizotinib suppresses downstream signaling involved in tumor-cell proliferation and survival. XALKORI is approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) and ROS1-positive metastatic NSCLC, and it is also indicated for certain pediatric and young adult patients with ALK-positive unresectable, relapsed, or refractory systemic anaplastic large cell lymphoma (ALCL) and patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumor (IMT). It is available as capsules and oral pellets, with dosing determined by the indication and patient population. Common adverse reactions include visual disorders, gastrointestinal effects such as diarrhea, nausea, and vomiting, edema, constipation, and elevated liver enzymes. The report provides XALKORI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the XALKORI Market Report

The report provides insights into:

• A comprehensive product overview including the XALKORI MoA, description, dosage and administration, research and development activities in approved indications like Anaplastic large cell lymphoma and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Non-Hodgkin’s lymphoma, Renal cell carcinoma, Neuroblastoma, and Solid tumours.
• Elaborated details on XALKORI regulatory milestones and other development activities have been provided in XALKORI market report.
• The report also highlights XALKORI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The XALKORI market report also covers the patents information, generic entry and impact on cost cut.
• The XALKORI market report contains current and forecasted XALKORI sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The XALKORI market report also features the SWOT analysis with analyst views for XALKORI in approved and potential indications.

Methodology

The XALKORI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XALKORI Analytical Perspective by DelveInsight

• In-depth XALKORI Market Assessment

This XALKORI sales market forecast report provides a detailed market assessment of XALKORI for approved indication like Anaplastic large cell lymphoma and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Non-Hodgkin’s lymphoma, Renal cell carcinoma, Neuroblastoma, and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted XALKORI sales data uptil 2034.

• XALKORI Clinical Assessment

The XALKORI market report provides the clinical trials information of XALKORI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

XALKORI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

XALKORI Market Potential & Revenue Forecast

• Projected market size for the XALKORI and its key indications
• Estimated XALKORI sales potential (XALKORI peak sales forecasts)
• XALKORI Pricing strategies and reimbursement landscape

XALKORI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• XALKORI Market positioning compared to existing treatments
• XALKORI Strengths & weaknesses relative to competitors

XALKORI Regulatory & Commercial Milestones

• XALKORI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

XALKORI Clinical Differentiation

• XALKORI Efficacy & safety advantages over existing drugs
• XALKORI Unique selling points

XALKORI Market Report Highlights

• In the coming years, the XALKORI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The XALKORI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XALKORI’s dominance.
• Other emerging products for Anaplastic large cell lymphoma and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Non-Hodgkin’s lymphoma, Renal cell carcinoma, Neuroblastoma, and Solid tumours are expected to give tough market competition to XALKORI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XALKORI in approved and potential indications.
• Analyse XALKORI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted XALKORI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of XALKORI in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of XALKORI? How strong is XALKORI’s clinical and commercial performance?
• What is XALKORI’s clinical trial status in each individual indications such as Anaplastic large cell lymphoma and Non-small cell lung cancer; as well as potential indication like Bladder cancer, Non-Hodgkin’s lymphoma, Renal cell carcinoma, Neuroblastoma, and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XALKORI Manufacturers?
• What are the key designations that have been granted to XALKORI for approved and potential indications? How are they going to impact XALKORI’s penetration in various geographies?
• What is the current and forecasted XALKORI market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of XALKORI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to XALKORI for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is XALKORI? What is the duration of therapy and what are the geographical variations in cost per patient?